Portola Phramaceuticals (PTLA)

[H2R]

EPS beats by $0.34, beats on revenue


Portola Pharmaceuticals (NASDAQ:PTLA):
* Q3 Non-GAAP EPS of -$0.53 beats by $0.34;
* GAAP EPS of -$0.68 beats by $0.20.
* Revenue of $36.8M (+159.2% Y/Y) beats by $2.16M.

https://seekingalpha.com/news/3514823-portola-pharmaceuticals-eps-beats-0_34-beats-revenue

That continues the positive trend on Andexxa and the balance sheet looks better.

- Andexxa Now Stocked in Approximately 550 U.S. Hospitals; 76% of U.S. Sales from Reorders -
- Expanded Market Opportunity with Strong Initial Ondexxya Demand in Europe -
- Strengthened Balance Sheet; Added Net Proceeds of $245 million in Third Quarter -

A good quarter.